Drug intelligence / Profile preview

rukangshu

Development stage: Unknown
Lead developer: Jiangsu Hengrui Medicine
Administration: Oral

Overview

Rukangshu is a Traditional Chinese Medicine (TCM) formulation, primarily available as an oral capsule, developed and manufactured by Jiangsu Hengrui Medicine. It is indicated for the treatment of breast hyperplasia (hyperplasia of mammary gland) and associated mastalgia (breast pain). In TCM theory, the formulation is designed to address syndromes of kidney deficiency, liver depression, and disharmony of the Chong and Ren channels. It is an approved Chinese Patent Medicine (CPM) in China and has been evaluated in large-scale clinical trials to further establish its safety and efficacy across broader patient demographics and syndrome subtypes, including its use in combination with other interventions like acupuncture.

Brand names: Rukangshu
Other names: Rukangshu Capsule乳康舒胶囊

Beyond the preview

Go deeper on rukangshu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rukangshu.

Explore the full profile